“Ide-cel demonstrated frequent, deep, and durable responses in heavily pretreated, highly relapsed/refractory patients with myeloma. Overall, ide-cel provides an attractive option for the treatment of patients with triple-class exposed relapsed/refractory myeloma."
A pair of off-the-shelf CAR T-cell agents have shown promise for the treatment of relapsed/refractory large B-cell or follicular lymphoma, according to the phase 1 ALPHA study.
Mark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.
"CheckMate 9LA met its primary end point of overall survival at the pre-planned interim analysis…With early separation of overall survival curves and lower progressive disease rates as best overall response, the hypothesis for this study design was validated."
The addition of tucatinib to treatment with trastuzumab and capecitabine resulted in more than a 60% reduction in the risk of central nervous system progression or death in both patients with previously treated HER2-positive metastatic breast cancer who have active or stable brain metastases.
Modest survival benefits were observed in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum compared with patients who received EP and placebo. Although progression-free survival rates reached the threshold for significance, overall survival rates failed to reach the prespecified threshold, according to data from the phase 3 KEYNOTE-604 trial.
Despite missing the primary end point of progression-free survival improvement, cediranib and olaparib demonstrated comparable activity with platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.
“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified."
According to the lead study author Jesus G. Berdeja, MD, the overall response rate was 100%, with a stringent complete response rate of 86%. Further, the progression-free survival rate was 86% at 9 months.
"Based on these results, we note that the combination of nivolumab and ipilimumab, which is now approved by the United States FDA, is a novel chemotherapy-sparing first-line treatment approach for advanced-stage non-small-cell lung cancer."
"In this trial, we show deep and durable responses with single-agent [belantamab mafodotin] were sustained with longer follow-up in this relapsed/refractory multiple myeloma population."
“Lu-PSMA is a novel class of therapy with high activity and relatively low toxicity, consistent with the results of prior single-center studies in phase II data. Lu-PSMA appears to represent a favorable treatment option compared to cabazitaxel in a selected population with high PSMA-expression.”
"Trastuzumab deruxtecan demonstrated clinical activity in this interim analysis, with a high ORR and durable response rate in a heavily pretreated population of patients with HER2-mutated NSCLC."
"Although patient numbers and follow-up were limited, savolitinib demonstrated encouraging efficacy and an improved safety profile versus sunitinib."
"We believe the TIVO-3 data demonstrate a favorable risk/benefit profile for tivozanib in the growing population of patients who have relapsed or become refractory to multiple lines of therapy, including checkpoint inhibitors."
Frontline treatment with the TIGIT inhibitor tiragolumab plus atezolizumab demonstrated greater efficacy versus single-agent checkpoint inhibitor therapy in locally advanced or metastatic non–small cell lung cancer, according to results of the phase 2 CITYSCAPE trial reported at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
David O'Malley, MD, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.
“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified. Clinical response looks promising."
Selinexor in combination with bortezomib and dexamethasone resulted in improvements in responses and outcomes compared with bortezomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to findings from the phase 3 BOSTON trial from the 2020 ASCO Virtual Scientific Program.
Given the higher efficacy of carfilzomib seen in recent phase 2 trials, investigators sought to determine if carfilzomib could replace bortezomib in the current standard of care triplet induction regimen in standard and intermediate risk NDMM, but the study failed.
"Based on the results of our study, women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit."
The risk for death from COVID-19 was greater for patients with stable cancer compared with patients who had no evidence of disease.
"It is a proof of concept of the efficacy of an immunotherapy in [patients with] gestational trophoblastic tumors , confirming the rationale we had."
"This is the first time that such a large precision oncology platform [involving] pediatric patients was assessed for its clinical benefit."
"Adjuvant osimertinib is the first targeted agent in a global randomized trial to show a statistically significant and clinically meaningful improvement in disease-free survival in patients with stage IB/II/IIIA EGFR mutation–positive non–small cell lung cancer."
"Pembrolizumab works in non-randomized studies in this group of patients with advanced disease. This randomized study demonstrates a huge benefit in the first-line [setting] with pembrolizumab and should be the new standard of care."
"Prior administration of chemotherapy is associated with increased risk of death [from COVID-19] while immunotherapy and tyrosine kinase inhibitors are not."
"Avelumab first-line maintenance in patients whose disease has not progressed with platinum-based induction therapy is a new first-line standard of care for advanced urothelial carcinoma."
“This study is 1 of the first [to report on a] chemoimmunotherapy combination in the second- and third-line setting of metastatic urothelial carcinoma."
Yousef Zakharia, MD, discussed recent phase I data from a study of seleno-L-methionine in combination with axitinib as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma. Zakharia recently presented these data as part of the American Urological Association Virtual Experience platform for the 2020 AUA Annual Meeting.